Medshape, Inc. v. Arthrex, Inc.

District Court, W.D. Texas·Decided August 29, 2025·No. 6:24-cv-00151·Unknown

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF TEXAS WACO DIVISION

MEDSHAPE, INC., TRILLIANT § SURGICAL LLC, (d/b/a ENOVIS FOOT § § AND ANKLE), and ENCORE § MEDICAL, L.P., § § Plaintiffs, § § Case No. 6:24-cv-00151-DTG v. § § § ARTHREX, INC. and ARTHREX § MANUFACTURING, INC. § § Defendants. §

CLAIM CONSTRUCTION ORDER

Pending before the Court is a claim construction dispute involving two terms from a single patent. The parties fully briefed their positions, the Court provided preliminary constructions, and the Court held a claim construction hearing on December 5, 2024. After hearing arguments of counsel, the Court took the construction of one term, “bone fragment,” under advisement and confirmed that its preliminary construction of the “substantially in an austenitic phase” terms would be adopted as the final construction. Dkt. No. 64 at 55:5-17. This order provides final constructions for both terms as follows. After the claim construction hearing, an additional dispute arose over whether the steps of claim 1 must be performed in a specific order. The defendant, Arthrex, Inc., moved for an additional claim construction to resolve this dispute. Dkt. No. 68. That motion was opposed and has been fully briefed, including a sur-reply. Dkt. Nos. 79, 81, 88. The Court finds a hearing on this additional dispute unnecessary and GRANTS this additional motion (Dkt. No. 68) for the reasons that follow. I. CLAIM CONSTRUCTION Claim construction starts with the general rule that claim terms are construed according to their ordinary meaning as understood by a person of skill in the relevant art. Phillips v. AWH Corp., 415 F.3d 1303, 1312-13 (Fed. Cir. 2005) (en banc); Alloc, Inc. v. Int’l Trade Comm’n, 342 F.3d 1361, 1368 (Fed. Cir. 2003); Azure Networks, LLC v. CSR PLC, 771 F.3d 1336, 1347

(Fed. Cir. 2014) (holding that there is a heavy presumption in favor of the ordinary meaning) cert. granted, judgment vacated, 135 S. Ct. 1846 (2015). To determine the construction, courts start by considering the intrinsic evidence, which includes the claims, specification, and prosecution history. Phillips, 415 F.3d at 1313-14. Extrinsic evidence—such as technical dictionaries, treatises, and expert testimony—can also be useful, but it is given less weight than the intrinsic evidence. Phillips, 415 F.3d at 1317-18 (quoting C.R. Bard, Inc., 388 F.3d at 862). There are two exceptions to the general rule in favor of ordinary meaning. These exceptions are “1) when a patentee sets out a definition and acts as his own lexicographer, or 2) when the patentee disavows the full scope of the claim term either in the specification or during

prosecution.” Golden Bridge Tech., Inc. v. Apple Inc., 758 F.3d 1362, 1365 (Fed. Cir. 2014) (quoting Thorner v. Sony Comput. Entm’t Am. LLC, 669 F.3d 1362, 1365 (Fed. Cir. 2012)); see also GE Lighting Sols., LLC v. AgiLight, Inc., 750 F.3d 1304, 1309 (Fed. Cir. 2014) (“[T]he specification and prosecution history only compel departure from the plain meaning in two instances: lexicography and disavowal.”). The standards for finding lexicography or disavowal are “exacting” with both requiring clear evidence. GE Lighting Sols., 750 F.3d at 1309. Proving disavowal requires clear and unmistakable evidence. Golden Bridge Tech., Inc., 758 F.3d at 1365. Patent claims must also particularly point out and distinctly claim the subject matter regarded as the invention. 35 U.S.C. § 112, ¶ 2. A claim, when viewed in light of the intrinsic evidence, must “inform those skilled in the art about the scope of the invention with reasonable certainty.” Nautilus Inc. v. Biosig Instruments, Inc., 572 U.S. 898, 910 (2014). If it does not, the claim fails § 112, ¶ 2 and is invalid as indefinite. Id. at 901. Whether a claim is indefinite is

determined from the perspective of one of ordinary skill in the art as of the time the application for the patent was filed. Id. at 911. As it is a challenge to the validity of a patent, proof of indefiniteness must be shown by clear and convincing evidence. BASF Corp. v. Johnson Matthey Inc., 875 F.3d 1360, 1365 (Fed. Cir. 2017). II. BACKGROUND This patent infringement case involves two asserted patents. One asserted patent is U.S. Patent No. 7,985,222, which is titled, “Osteosynthetic Implants and Methods of Use and Manufacture.” Dkt. No. 35-1. The other asserted patent is U.S. Patent No. 8,491,583, which is titled, “Intramedullary Medical Device and Methods of Use and Manufacture.” Dkt. No. 35-2.

Free access — add to your briefcase to read the full text and ask questions with AI

Medshape, Inc. v. Arthrex, Inc., (W.D. Tex. 2025).

Medshape, Inc. v. Arthrex, Inc. (Medshape, Inc. v. Arthrex, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Baran v. Medical Device Technologies, Inc.
616 F.3d 1309 (Federal Circuit, 2010)
Daiichi Sankyo Co., Ltd. v. Apotex, Inc.
501 F.3d 1254 (Federal Circuit, 2007)
Thorner v. Sony Computer Entertainment America LLC
669 F.3d 1362 (Federal Circuit, 2012)
Baldwin Graphic Systems, Inc. v. Siebert, Inc.
512 F.3d 1338 (Federal Circuit, 2008)
Ge Lighting Solutions, LLC v. Agilight, Inc.
750 F.3d 1304 (Federal Circuit, 2014)
Nautilus, Inc. v. Biosig Instruments, Inc.
134 S. Ct. 2120 (Supreme Court, 2014)
Golden Bridge Technology, Inc. v. Apple Inc.
758 F.3d 1362 (Federal Circuit, 2014)
Azure Networks, LLC v. Csr, Plc
771 F.3d 1336 (Federal Circuit, 2014)
Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc.
789 F.3d 1335 (Federal Circuit, 2015)
Tecsec, Inc. v. Adobe Systems Incorporated
658 F. App'x 570 (Federal Circuit, 2016)
Basf Corporation v. Johnson Matthey Inc.
875 F.3d 1360 (Federal Circuit, 2017)
Cordis Corp. v. Medtronic Ave, Inc.
339 F.3d 1352 (Federal Circuit, 2003)
Dana Corp. v. American Axle & Manufacturing, Inc.
110 F. App'x 871 (Federal Circuit, 2004)
Vascular Solutions LLC v. Medtronic, Inc.
117 F.4th 1361 (Federal Circuit, 2024)